Compare Adaptive Biotechnologies Corp (ADPT) vs Five9 Inc (FIVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Five9 Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Five9 Inc trades at $24.17 (market cap $1.91B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Five9 Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | FIVN | |
|---|---|---|
Market Cap | $3.33B | $1.91B |
Sector | Health | Technology |
52-Week High | $22.37 | $29.16 |
52-Week Low | $10.24 | $13.61 |
Enterprise Value | $3.19B | $1.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Five9 (FIVN) trades at $24.99, up 6.59% today, showing strong momentum after consistently beating earnings estimates. The stock maintains bullish technical signals with moving averages supporting upward trends, though RSI levels indicate potential overbought conditions. Revenue growth has accelerated from $779M in 2022 to $1.15B in 2025, with the company achieving profitability for the first time in 2025 with $39M net income. Recent leadership appointments and AI product launches signal continued innovation in the CX platform space.
The outlook remains positive with 61% analyst buy ratings and a $27 consensus target offering 8% upside. Key catalysts include sustained revenue growth and margin expansion, while risks involve ongoing fiduciary investigations and competitive pressures in the cloud contact center market. The stock's premium valuation (P/E 37.1) requires continued execution to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
